NASDAQ:TRVI

Trevi Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy TRVI

*Your capital is at risk

$13.45

-0.0500 (-0.370%)

At Close: Jun 03, 2026

Trevi Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 21.95. In total, the insiders bought 6.82M and sold 14.99M TRVI shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	21.95
● Buy	6.82M shares
● Sell	14.99M shares
84% Buy Activity Negligible or No Correlation
Buy Signal Medium Confidence Feb 19, 2026 Analysis Breakdown: Supported by a positive Insider Power Score of 21.95. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (84% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
May 31, 2025 Buy	Performance Stock Option (right to buy) A-Award	Galletta Christopher See Remarks	Officer	8 550 Value: $20.3K
May 31, 2025 Buy	Performance Stock Option (right to buy) A-Award	Sciascia Thomas Chief Scientific Officer	Officer	60 000 Value: $142.8K
May 31, 2025 Buy	Performance Stock Option (right to buy) A-Award	Delfini Lisa Chief Financial Officer	C-Suite Officer	72 000 Value: $171.4K
May 31, 2025 Buy	Performance Stock Option (right to buy) A-Award	Simon Farrell Chief Commercial Officer	Officer	72 000 Value: $171.4K
May 31, 2025 Buy	Performance Stock Option (right to buy) A-Award	Good Jennifer L President & CEO	CEO / President	102 000 Value: $242.8K
May 31, 2025 Buy	Performance Stock Option (right to buy) A-Award	Sciascia Thomas Chief Scientific Officer	Officer	60 000 Value: $142.8K
May 31, 2025 Buy	Performance Stock Option (right to buy) A-Award	Galletta Christopher See Remarks	Officer	8 550 Value: $20.3K
May 31, 2025 Buy	Performance Stock Option (right to buy) A-Award	Good Jennifer L President & CEO	CEO / President	102 000 Value: $242.8K
May 31, 2025 Buy	Performance Stock Option (right to buy) A-Award	Simon Farrell Chief Commercial Officer	Officer	72 000 Value: $171.4K
May 31, 2025 Buy	Performance Stock Option (right to buy) A-Award	Delfini Lisa Chief Financial Officer	C-Suite Officer	72 000 Value: $171.4K
Apr 17, 2025 Sell	3.5-Year Common Stock Warrant X-InTheMoney	New Enterprise Associates 16, L.p. 10 Percent Owner	10% Owner	1 851 852 Value: $2.54M
Apr 17, 2025 Sell	3.5-Year Common Stock Warrant X-InTheMoney	Walker Paul Edward 10 Percent Owner	10% Owner	1 851 852 Value: $2.54M
Apr 17, 2025 Sell	3.5-Year Common Stock Warrant X-InTheMoney	Makhzoumi Mohamad 10 Percent Owner	10% Owner	1 851 852 Value: $2.54M
Apr 17, 2025 Sell	3.5-Year Common Stock Warrant X-InTheMoney	Florence Anthony A. Jr. 10 Percent Owner	10% Owner	1 851 852 Value: $2.54M
Apr 17, 2025 Sell	3.5-Year Common Stock Warrant X-InTheMoney	Sandell Scott D 10 Percent Owner	10% Owner	1 851 852 Value: $2.54M
Apr 17, 2025 Sell	3.5-Year Common Stock Warrant X-InTheMoney	Behbahani Ali 10 Percent Owner	10% Owner	1 851 852 Value: $2.54M
Apr 17, 2025 Sell	3.5-Year Common Stock Warrant X-InTheMoney	Baskett Forest 10 Percent Owner	10% Owner	1 851 852 Value: $2.54M
Apr 17, 2025 Sell	3.5-Year Common Stock Warrant X-InTheMoney	Chang Carmen 10 Percent Owner	10% Owner	1 851 852 Value: $2.54M
Mar 25, 2025 Buy	Common Stock M-Exempt	Sciascia Thomas Chief Scientific Officer	Officer	2 631 Value: $4K
Mar 25, 2025 Sell	Common Stock S-Sale	Sciascia Thomas Chief Scientific Officer	Officer	2 631 Value: $17.4K
Mar 25, 2025 Buy	Stock Option (right to buy) M-Exempt	Sciascia Thomas Chief Scientific Officer	Officer	2 631 Value: $4K
Mar 25, 2025 Buy	Stock Option (right to buy) M-Exempt	Sciascia Thomas Chief Scientific Officer	Officer	2 631 Value: $4K
Mar 25, 2025 Sell	Common Stock S-Sale	Sciascia Thomas Chief Scientific Officer	Officer	2 631 Value: $17.4K
Mar 25, 2025 Buy	Common Stock M-Exempt	Sciascia Thomas Chief Scientific Officer	Officer	2 631 Value: $4K
Mar 21, 2025 Buy	Common Stock M-Exempt	Good Jennifer L President & CEO	CEO / President	5 263 Value: $8K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT TREVI THERAPEUTICS INC.

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo P...

Read Full Profile Here